Patents by Inventor Erkki Truve

Erkki Truve has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20130029417
    Abstract: The invention describes use of RNA silencing suppressors or interactors of the suppressors to bring the expression of microRNAs involved in any disease, including malignant neoplasia, back to its normal level. More specifically the present invention provides a method to regulate many miRNAs at the same time. Most of the suppressors according to this invention are coded by plant viruses that unexpectedly can affect RNA silencing and modulate miRNA expression levels in mammalian cells. Also suppressors of endogenous origin are described as able to modulate miRNA expression levels.
    Type: Application
    Filed: February 18, 2011
    Publication date: January 31, 2013
    Applicants: AS VAHIUURINGUTE TEHNOLOOGIA ARENDUSKESKUS, TALLINN UNIVERSITY OF TECHNOLOGY
    Inventors: Maria Cecilia Sarmiento Guerin, Kairi Karblane, Illar Pata, Erkki Truve, Pille Pata
  • Publication number: 20110152346
    Abstract: The invention is concerned with the use of oligonucleotide analogs that contain specifically modified DNA bases to be used in hybridization of nucleic acids, polymerase chain reaction (PCR) and siRNA-mediated gene silencing (RNAi).
    Type: Application
    Filed: November 5, 2008
    Publication date: June 23, 2011
    Applicant: Baltic Technology Development Ltd.
    Inventors: Mati Karleson, Erkki Truve, Allan Olspert, Cecilia Sarmiento, Mart Saarma
  • Patent number: 5589625
    Abstract: This invention discloses transgenic plants, such as transgenic tobacco and potato, having resistance to multiple viral taxonomic groups using parts of the 2,5A oligoadenylate pathway. In particular, said plants are genetically engineered to contain a DNA sequence encoding at least one polypeptide having a 2,5A synthetase activity. By this means a step in the 2,5A oligoadenylate pathway heretofore believed to be missing in all plants is provided so that viral infection in the transgenic plants is inhibited via a 2,5A dependent endonuclease. Moreover, this invention relates to a process for the production of said transgenic plants by transfection with a genetically engineered DNA sequence encoding at least one polypeptide having a 2,5A synthetase activity.
    Type: Grant
    Filed: January 18, 1995
    Date of Patent: December 31, 1996
    Assignee: Kemira Oy, Biotech
    Inventors: Mart Saarma, Merikke Kelve, Erkki Truve, Teemu Teeri